BCYC earnings: next report 2026-08-14, real EPS beat/miss history, analyst consensus Buy, P/E -1.34. Updated 2026-07-23.
Bicycle Therapeutics (BCYC) Research Hub
Bicycle Therapeutics (BCYC) trades on NASDAQ, GB in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 3.86 USD (-3.74%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.34, market cap 0.29B. This hub links to the full technical, earnings and options research available for BCYC.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, GB |
| Last close | 3.86 USD (-3.74%) |
| 52-week range | 3.8 USD – 4.51 USD |
| Trend regime | Range |
| 14-day RSI | 39.9 (Bearish) |
| Trailing P/E | -1.34 |
| Market cap | 0.29B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-14 |
Available research for BCYC
Covered Call on BCYC: how it works, illustrative setup around the real 3.86 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on BCYC: how it works, illustrative setup around the real 3.86 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on BCYC: how it works, illustrative setup around the real 3.86 USD price, max profit/loss, breakeven and when to use it. Educational.
BCYC technical analysis: range, last 3.86 USD, RSI 39.9, 52w range 3.8 USD–4.51 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is BCYC in?
Bicycle Therapeutics (BCYC) is classified under Healthcare (Biotechnology), listed on NASDAQ, GB.
Is BCYC in an uptrend or downtrend?
As of 2026-09-11, BCYC is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is BCYC's trailing P/E ratio?
BCYC's trailing P/E is -1.34, with a market cap of 0.29B. See the earnings research page for full valuation detail.
When does BCYC next report earnings?
BCYC is next scheduled to report earnings on 2026-08-14, with a consensus EPS estimate of -0.564 USD.